PARP1 inhibitor

DRUG CLASS:

PARP1 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1	abiraterone/niraparib Sensitive: A1 - Approval abiraterone / niraparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3	BSI 201 Sensitive: C3 – Early Trials BSI 201 Sensitive : C3
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4	BSI 201 Sensitive: C4 – Case Studies BSI 201 Sensitive : C4
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D	TQB3823 Sensitive: D – Preclinical TQB3823 Sensitive : D
HRD	HER2 Positive Breast Cancer	HRD	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive : D	fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive: D – Preclinical fam-trastuzumab deruxtecan-nxki + AZD5305 Sensitive : D
PARP1 underexpression	Soft Tissue Sarcoma	PARP1 underexpression	Soft Tissue Sarcoma	ATR inhibitor + PARP1 inhibitor Sensitive: D – Preclinical ATR inhibitor + PARP1 inhibitor Sensitive : D	ATR inhibitor + PARP1 inhibitor Sensitive: D – Preclinical ATR inhibitor + PARP1 inhibitor Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	VIO-01 Sensitive: D – Preclinical VIO-01 Sensitive : D	VIO-01 Sensitive: D – Preclinical VIO-01 Sensitive : D
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	olaparib + VIO-01 Sensitive: D – Preclinical olaparib + VIO-01 Sensitive : D	olaparib + VIO-01 Sensitive: D – Preclinical olaparib + VIO-01 Sensitive : D
HRD	Colorectal Adenocarcinoma	HRD	Colorectal Adenocarcinoma	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
HRD	Breast Cancer	HRD	Breast Cancer	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D	AZD5305 Sensitive: D – Preclinical AZD5305 Sensitive : D
HRD	Solid Tumor	HRD	Solid Tumor	VIO-01 Sensitive: D – Preclinical VIO-01 Sensitive : D	VIO-01 Sensitive: D – Preclinical VIO-01 Sensitive : D
VTCN1 underexpression	Solid Tumor	VTCN1 underexpression	Solid Tumor	AZD8205 + AZD5305 Sensitive: D – Preclinical AZD8205 + AZD5305 Sensitive : D	AZD8205 + AZD5305 Sensitive: D – Preclinical AZD8205 + AZD5305 Sensitive : D
MGMT promoter methylation	Glioma	MGMT promoter methylation	Glioma	temozolomide + AZD9574 Sensitive: D – Preclinical temozolomide + AZD9574 Sensitive : D	temozolomide + AZD9574 Sensitive: D – Preclinical temozolomide + AZD9574 Sensitive : D

PARP1 inhibitor

PARP1 inhibitor

Associations(21)

Associations
(21)